Status:
UNKNOWN
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)
Lead Sponsor:
University Hospital, Brest
Conditions:
Lung Cancer Stage III
Lung Cancer Stage IV
Eligibility:
All Genders
18+ years
Brief Summary
Pembrolizumab has been approved for first-line locally advanced or metastatic NSCLC with a tumor proportion score (TPS) ≥50% for PDL1, based on the results of KEYNOTE-024. However, even with a positi...
Detailed Description
Pembrolizumab has been approved for first-line locally advanced or metastatic NSCLC with a tumor proportion score (TPS) ≥50% for PDL1, based on the results of KEYNOTE-024. However, even with a positi...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Histologically or cytologically proven non-small-cell lung cancer (NSCLC)
- Stage IV NSCLC. Stage III NSCLC unresectable and not amenable to radiotherapy
- PD-L1 expression ≥ 50%.
- No previous systemic treatment for NSCLC.
- Patients treated for 1st-line metastatic disease with immunotherapy alone (pembrolizumab)
- No opposition expressed
- Patient affiliated to a social security scheme
Exclusion
- PD-L1 expression \<50
- Neuroendocrine tumors
- Secondarily metastatic patients
- Previous treatments
- Opposition formulated
- Patient under legal protection (guardianship, curatorship, etc.)
Key Trial Info
Start Date :
August 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2024
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT05996263
Start Date
August 1 2023
End Date
August 31 2024
Last Update
August 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Brest
Brest, France, 29609